{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:00:01Z","timestamp":1790204401401,"version":"4.1.0"},"reference-count":0,"publisher":"Pasifika Medical Association Group","issue":"1642","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NZMJ"],"abstract":"<jats:p>aim: From February 2026, vocationally trained general practitioners and nurse practitioners in Aotearoa New Zealand are authorised\nto initiate stimulant medication for adults with attention-deficit\/hyperactivity disorder (ADHD), marking a shift from a predominantly\nsecondary care model. This viewpoint article examines the clinical, ethical and service-level implications of this regulatory change,\nwith particular attention to equity, diagnostic quality, cost and sustainability in primary care.\nmethods: This viewpoint draws on Aotearoa New Zealand policy documents, international clinical guidance and selected peerreviewed\nliterature to inform a policy and equity-focussed analysis of expanded stimulant prescribing authority.\nresults: The policy change has the potential to improve access to ADHD treatment; however, the absence of mandated training,\ncompetency standards or operational guidance raises concerns about diagnostic quality, management of comorbidity and prescribing\nsafety. The time-intensive nature of adult ADHD assessment presents workload and resourcing challenges for primary care, and\nmultiple service delivery models are likely to emerge with variable equity implications.\nconclusion: Expanded prescribing authority may improve access, but without appropriate training, resourcing and implementation\nframeworks, benefits may be unevenly realised. Clear standards and equity-centred service design are essential.<\/jats:p>","DOI":"10.26635\/6965.7381","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:08:12Z","timestamp":1790201292000},"page":"156-161","source":"Crossref","is-referenced-by-count":0,"title":["Beyond prescribing rights: designing equitable and sustainable attentiondeficit\/ hyperactivity disorder care pathways in Aotearoa New Zealand"],"prefix":"10.26635","volume":"139","author":[{"given":"Steven","family":"Lillis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Oertly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Wheaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron","family":"Rangiwai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11177","published-online":{"date-parts":[[2026,9,25]]},"container-title":["New Zealand Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:08:16Z","timestamp":1790201296000},"score":1,"resource":{"primary":{"URL":"https:\/\/nzmj.org.nz\/journal\/vol-139-no-1642\/beyond-prescribing-rights-designing-equitable-and-sustainable-attention-deficit-hyperactivity-disorder-care-pathways-in-aotearoa"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":0,"journal-issue":{"issue":"1642","published-online":{"date-parts":[[2026,9,25]]}},"URL":"https:\/\/doi.org\/10.26635\/6965.7381","relation":{},"ISSN":["1175-8716"],"issn-type":[{"value":"1175-8716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]}}}